TY  - JOUR

T1  - Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

JO  - Cancers

UR  - http://dx.doi.org/10.3390/cancers13194846

PY  - 2021/09/28

AU  - Mouritzen MT

AU  - Carus A

AU  - Ladekarl M

AU  - Meldgaard P

AU  - Nielsen AWM

AU  - Livbjerg A

AU  - Larsen JW

AU  - Skuladottir H

AU  - Kristiansen C

AU  - Wedervang K

AU  - Schytte T et al

ED  - 

DO  - DOI: 10.3390/cancers13194846

PB  - MDPI AG

VL  - 13

IS  - 19

SP  - 4846

EP  - 4846

Y2  - 2024/12/22

ER  -